HOME ASBESTOS DRUGS POLLUTANTS ACCIDENTS MALPRACTICE STORY OF OUR FIRM

Saturday, July 19, 2008

Clinical Trials for Mesothelioma Patients: Cisplatin, Imatinib Mesylate, and Pemetrexed Inclusion Criteria

Read about the inclusion criteria for a current clinical trial being conducted to study the effects of Cisplatin, Imatinib Mesylate, and Pemetrexed or patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, this study is only being conducted in Lille, France.

Inclusion Criteria:
1. A written, voluntary informed consent form must be completed prior to beginning any study procedure.

2. Patients >/= 18 years of age.

3. Histologically documented diagnosis of malignant mesothelioma.

4. Performance status 0-2 (ECOG)

5. Pts must have adequate hepatic, renal,& bone marrow function, defined as the following:(1) total bilirubin /= 1.5x10^9/L;(5) platelets>/=100 x 10^9/L.Note:Renal function is only based on serum creatinine level /= 45mg/dl.

6. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.

7. Patients who have not received prior chemotherapy for their metastatic or recurrent unresectable malignant mesothelioma; with the exception of patients who have recurrent mesothelioma after induction chemotherapy followed by definitive treatment (surgery +/- radiotherapy). Patients must have had 2 or fewer cycles/doses of induction chemotherapy and must have had tumor response to the induction therapy.

8. Patients must have documented unresectable malignant mesothelioma (pleural or peritoneal).

9. Patients with treated brain metastasis who have stable brain disease (i.e. no steroids at least 4 weeks prior to study enrollment).

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney


Mesothelioma & Asbestosis Mortalities Across the US: 1979-2001 (c/o EWG)

“We have seen first-hand how asbestos has wreaked havoc on Americans working in naval shipyards, automobile plants, and the construction industry. Most often this is through their employers’ conscious choice for profits over a worker's health.”

-- Joseph Patrick Williams, a trial attorney in the Asbestos Litigation department of Weitz & Luxenberg

CONTACT WEITZ & LUXENBERG FOR A FREE LEGAL EVALUATION OF YOUR CASE

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
No
Were you diagnosed with lung cancer? Yes
No
Were you diagnosed with Mesothelioma? yes
no
What is your date of diagnosis?
Additional Comments
Best time to call?

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

TABLE OF CONTENTS
Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos


IN THIS SECTION
Antineoplaston therapy for mesothelioma patients
Antineoplaston trial for mesothelioma patients
Antineoplaston clinical trial for mesothelioma
Antineoplaston therapy for mesothelioma patients
Antineoplaston test for mesothelioma patients
AZD2171 therapy for mesothelioma patients
AZD2171 trial for mesothelioma patients
AZD2171 trial for mesothelioma disease
Mesothelioma patient study of AZD2171 effects
AZD2171 therapy for mesothelioma patients
Contact info for mesothelioma AZD2171 facilities
Current Bortezomib therapy for mesothelioma
Bortezomib trial description for mesothelioma
Outcomes of Bortezomib against mesothelioma cancer
Criteria of Bortezomib study on mesothelioma test
Effects of Bortezomib trial on mesothelioma cancer
Bortezomib therapy for mesothelioma patients
Current Dasatinib therapy for mesothelioma
NSC 732517 trial description for mesothelioma
NSC 732517 trial for mesothelioma patients
Eligibility for mesothelioma trial of NSC 732517
Mesothelioma patient profile for NSC 732517 trial
Mesothelioma therapy criteria to test NSC 732517
Information on NSC 732517 trial for mesothelioma
Bortezomib therapy for mesothelioma patients
Bortezomib and Cisplatin in mesothelioma trial
Cisplatin therapy for mesothelioma patients
Bortezomib and Cisplatin in mesothelioma trial
Mesothelioma therapy criteria to test NSC 732517
Information on NSC 732517 trial for mesothelioma
Current Imatinib therapy for mesothelioma patients
Imatinib Mesylate trial for mesothelioma patients
Outcomes of Imatinib against mesothelioma cancer
Recruitment data to test Imatinib on mesothelioma
Inclusion standard in Imatinib mesothelioma trial
Exclusion standard in Imatinib mesothelioma trial
Contact info for Imatinib mesothelioma study
Current Immunotoxin therapy: mesothelioma patients
Immunotoxin therapy for mesothelioma patients
Objectives of Immunotoxin trial on mesothelioma
Study outline for Immunotoxin mesothelioma trial
Disease traits in Immunotoxin mesothelioma trial
Patient traits: Immunotoxin mesothelioma trial
Contact info for Immunotoxin mesothelioma program
Early mesothelioma symptoms from Canada asbestos
Canada study criteria of early mesothelioma traits
Contact info for mesothelioma program in Canada
Cisplatin and Pemetrexed therapy for mesothelioma
Description of Pemetrexed mesothelioma study
Inclusion standard in Pemetrexed mesothelioma test
Exclusion standard in Pemetrexed mesothelioma test
Contact info for Pemetrexed mesothelioma study
NGR for mesothelioma
NGR drug trials against mesothelioma
NGR for mesothelioma study
Exclusion criteria for mesothelioma NGR study
Contact for Antineoplaston test on mesothelioma
Pazopanib for mesothelioma patients
Pazopanib for mesothelioma study
Pazopanib inclusion criteria at mesothelioma trial
Patient criteria for mesothelioma Pazopanib study
Pazopanib for mesothelioma therapy
Pemetrexed drug for mesothelioma patients
Pemetrexed drug study for mesothelioma patients
Pemetrexed and cisplatin for mesothelioma patients
Pemetrexed study outline for mesothelioma patients
Pemetrexed disodium drug trial for mesothelioma
Pemetrexed trials for mesothelioma patients
Pemetrexed trials for mesothelioma patients
Contact info: Pemetrexed trial for mesothelioma
Vitamin B12 test on mesothelioma patients
Vitamin B12 study on mesothelioma patients
Outcome of Vitamin B12 on mesothelioma patients
Vitamin B12 outline for mesothelioma study
Patient criteria for B12 study on mesothelioma
Criteria of Vitamin B12 therapy on mesothelioma
Contact info of mesothelioma clinical trial of B12
Novartis LBH589 for mesothelioma
Novartis LBH589 for mesothelioma study
LBH589 trial for mesothelioma
Clinical LBH589 for mesothelioma
Clinical trial for esophageal cancer, mesothelioma
Clinical trial of hTNF for mesothelioma
Valproate for Mesothelioma
Vandetanib tested for mesothelioma
Vorinostat tested for mesothelioma


RETURN BACK TO
Mesothelioma
Symptoms, Stages, Treatment of Mesothelioma
Treatment
see also:

AZD2171 therapy for mesothelioma patients Therapy program to treat mesothelioma patients with AZD2171
Read about AZD2171 therapy trial with mesothelioma patients

Clinical trial of hTNF for mesothelioma Clinical trial of NGR-hTNF as a single agent in mesothelioma patients
Read about NGR-hTNF as a single agent in mesothelioma patients

Clinical trials on asbestos illness: mesothelioma Info about clinical trials on mesothelioma, an asbestos illness
Information on clinical trials of the asbestos illness, mesothelioma

Name Phone Email
Do you have a legal question? Ask us!   strictly confidential
Your Question